Aeter­na dis­con­tin­ues vac­cine de­vel­op­ment; Idera re­brands as Ac­er­a­gen

As biotechs start to de­tail 2023 plans — M&A, new em­phases in drug R&D and more with in­vestors — oth­ers are start­ing to trim back or us­ing the new year as an op­por­tu­ni­ty to do an about-face and try and start with a clean slate.

Three such biotechs un­veiled next steps for their re­spec­tive com­pa­nies Tues­day morn­ing.

Aeter­na ax­es ear­ly-stage vac­cine pipeline af­ter reac­quir­ing re­gion­al rights to sole prod­uct

Aeter­na Zen­taris is cut­ting its work on a vac­cine plat­form, which the biotech said had po­ten­tial ap­pli­ca­tions against chlamy­dia and Covid-19. How­ev­er, the com­pa­ny said it had not been able to se­lect a clin­i­cal de­vel­op­ment can­di­date for a Covid-19 vac­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER